NFKB1 and breast carcinoma: Although the use of ARBs and ACEIs in breast cancer treatment is debated, the inhibition of breast cancer growth (47), angiogenesis (53), and metastasis (50) were achieved by administrating AT1R blockers, which downregulate VEGF in human breast cancer cells (39) and inhibit NF-κB (46).